Eli Lilly's Leukemia Treatment Jaypirca Gets FDA Approval
01 Dezembro 2023 - 8:06PM
Dow Jones News
By Denny Jacob
Eli Lilly's Jaypirca was approved by the Food and Drug
Administration to treat adults with chronic lymphocytic leukemia or
small lymphocytic lymphoma who have received at least two prior
lines of therapy.
The Indianapolis-based pharmaceutical company said Friday that
Jaypirca was approved under the FDA's accelerated approval pathway
based on results from a trial.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 01, 2023 17:51 ET (22:51 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Eli Lilly (NYSE:LLY)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024